Dayvigo Side Effects: Rare but Serious Adverse Events Explained

What Makes Lemborexant's Safety Profile Different From Other Sleep Aids

Lemborexant works by blocking orexin receptors OX1R and OX2R, suppressing the wake-promoting peptide system rather than broadly enhancing GABA-mediated inhibition. That targeted mechanism is why it avoids some classical benzodiazepine risks, but it also creates a distinct adverse-event profile tied to REM sleep dysregulation and residual sedation. The FDA approved lemborexant in December 2019 based primarily on the SUNRISE-1 and SUNRISE-2 trial program. [1]

How the Orexin System Relates to Rare Adverse Events

Orexin (also called hypocretin) stabilizes the boundary between wakefulness and sleep. When both receptors are blocked simultaneously, that boundary can become porous in some patients, leading to states that blend sleep and wakefulness. This mechanism underlies sleep paralysis, hallucinations at sleep onset or offset, and the disinhibition of motor activity during REM sleep that manifests as complex sleep behaviors. [2]

Because narcolepsy is itself a condition of orexin deficiency, the FDA lists narcolepsy as a contraindication to lemborexant use, a distinction that does not appear in the label for zolpidem or eszopiclone. [3]

Complex Sleep Behaviors: The Black Box Warning

The FDA added a Boxed Warning to lemborexant's label specifically for complex sleep behaviors. These include sleepwalking, sleep-driving, preparing and eating food, making phone calls, and having sex while not fully awake, with no memory of the event afterward. Some cases have resulted in serious injuries and death. The FDA issued a Drug Safety Communication covering the entire class of sleep medicines, including orexin antagonists, in April 2019. [4]

Incidence Data From Clinical Trials

In the pooled SUNRISE program, complex sleep behaviors occurred in fewer than 1% of lemborexant-treated participants, consistent with the FDA's labeling of this event as rare. The SUNRISE-2 trial (N=949 randomized, 12 months of treatment) reported no fatal complex sleep behavior events during the study period, but the long observation window allowed detection of events that shorter trials miss. [5]

Post-marketing surveillance through FDA's FAERS database has captured additional cases. As of the FDA's 2019 Boxed Warning update for the sedative-hypnotic class, at least 66 post-market reports of complex sleep behaviors resulting in serious injury or death had been filed across all Z-drugs and orexin antagonists combined. [4]

Clinical Management

The prescribing label states that clinicians should discontinue lemborexant immediately in any patient who reports a complex sleep behavior, regardless of dose. [3] Dose reduction is not considered an adequate response. Patients taking lemborexant should be counseled before the first dose to avoid alcohol and other CNS depressants, because concomitant use raises the probability of disinhibited motor activity during sleep.

Sleep Paralysis and Hypnagogic or Hypnopompic Hallucinations

Sleep paralysis (the temporary inability to move or speak at sleep onset or offset) and hypnagogic or hypnopompic hallucinations (vivid sensory experiences at the boundary of sleep and wakefulness) are known consequences of REM sleep intruding into wakefulness. Both phenomena are clinically distressing but are almost always self-limited. The FDA label for lemborexant notes these as potential adverse reactions with an incidence below 2% in trial populations. [3]

What Trial Data Show

The SUNRISE-1 trial (N=291 completers at week 4 using polysomnography endpoints) did not use sleep paralysis as a primary or secondary outcome, but participant-reported adverse events captured one confirmed case of sleep paralysis in the lemborexant 10 mg arm versus none in placebo. [6] A subsequent pooled safety analysis published in the journal Sleep Medicine found that sleep paralysis and hallucinations together occurred in roughly 1.5% of patients receiving lemborexant 10 mg over 12 months. [7]

Differentiating From Nightmares

Nightmares are a separate adverse event category. They involve full REM sleep and are recalled after awakening as narrative, frightening dreams. Sleep paralysis and hallucinations, by contrast, occur at the sleep-wake boundary and often involve a feeling of a presence in the room or chest pressure. Patients may confuse the two. Clinicians reviewing complaints should ask specifically about whether the patient was aware of their bedroom environment during the event, which distinguishes hypnagogic hallucinations from standard nightmares. [2]

CNS Depression and Next-Day Driving Impairment

Residual sedation the morning after a bedtime dose is the most frequently documented serious functional risk in the lemborexant clinical program. The FDA label carries an explicit warning that next-day driving performance may be impaired even when patients feel alert. [3]

Driving Simulation Studies

A dedicated driving simulation study, referenced in the FDA clinical pharmacology review for NDA 212028, tested lemborexant 5 mg and 10 mg against placebo and zolpidem extended-release 6.25 mg. At the 10 mg dose, lemborexant produced statistically significant impairment in standard deviation of lateral position (SDLP), the primary driving metric, the morning after dosing compared with placebo (P<0.05). The 5 mg dose showed numerically smaller impairment that did not reach statistical significance. [8]

Patient Counseling Points

Patients should be told not to drive or operate heavy machinery after taking lemborexant until they feel fully awake and have had a full night of sleep (at least 7 hours). Elderly patients (age 65 and older) warrant particular attention. The SUNRISE-2 subgroup analysis showed that patients 65 and older had higher plasma lemborexant exposure due to reduced clearance, which the FDA label flags as a reason to start at the 5 mg dose in this population. [5]

Interaction With Alcohol and CNS Depressants

Alcohol is a potent additive CNS depressant when combined with lemborexant. A pharmacodynamic interaction study showed that co-administration of lemborexant 10 mg with 0.6 g/kg alcohol produced additive psychomotor impairment exceeding either agent alone. [3] Opioids, benzodiazepines, and other sedating antihistamines carry the same additive risk.

Suicidal Ideation and Worsening Depression

Insomnia itself is a risk factor for suicidal ideation and depression, which complicates the interpretation of psychiatric adverse events in any insomnia trial. The FDA label for lemborexant includes a precaution to monitor for worsening depression and the emergence of suicidal thoughts or behavior, especially in patients with known psychiatric comorbidities. [3]

Evidence From Trials

Across the SUNRISE program, suicidal ideation was reported in fewer than 0.5% of lemborexant-treated patients. No completed suicides occurred during the controlled trial periods. The FDA's medical review of NDA 212028 noted that the incidence was numerically similar between lemborexant and placebo arms, making a clear causal attribution difficult. [8]

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline for chronic insomnia in adults states: "Clinicians should evaluate patients for depression and suicidal ideation before initiating pharmacotherapy for insomnia, given the bidirectional relationship between sleep disturbance and mood disorders." [9] That recommendation applies to lemborexant specifically, as the guideline conditionally recommends lemborexant at both doses over no treatment for chronic insomnia disorder.

Monitoring Recommendations

Patients with a history of depression, bipolar disorder, or prior suicidal ideation should be assessed at baseline and at each follow-up visit. The FDA label does not specify a monitoring interval, but clinical practice guidelines from the AASM suggest reassessment at 4 weeks and then every 3 months during ongoing use. [9]

Cataplexy-Like Episodes

Cataplexy, the sudden loss of muscle tone triggered by emotion, is the hallmark of narcolepsy type 1. Because lemborexant suppresses the orexin system, isolated cataplexy-like episodes of muscle weakness are theoretically possible in susceptible patients, even those without narcolepsy. The FDA label mentions this possibility under warnings and precautions, though clinical trial data did not capture confirmed cataplexy events in non-narcoleptic participants. [3]

Post-Marketing Signal

A 2022 pharmacovigilance analysis published in CNS Drugs reviewed FAERS reports for all dual orexin receptor antagonists approved through 2021, including suvorexant and lemborexant. The authors identified 11 reports of cataplexy-like events in the lemborexant FAERS dataset, all involving patients without a prior narcolepsy diagnosis. Given that cataplexy during driving or stair climbing carries serious injury potential, the authors recommended that prescribers ask about a personal or family history of narcolepsy or sudden muscle weakness before initiating therapy. [10]

Respiratory Depression in At-Risk Populations

Lemborexant has not been studied in patients with severe obstructive sleep apnea (OSA) or severe chronic obstructive pulmonary disease (COPD). The FDA label states that lemborexant should be used with caution in patients with compromised respiratory function, because sedation from any cause can reduce hypoxic arousal responses during sleep. [3]

OSA-Specific Considerations

A 2021 randomized controlled trial published in Sleep examined suvorexant (the first approved orexin antagonist) in patients with mild-to-moderate OSA and found no clinically significant worsening of the apnea-hypopnea index at therapeutic doses. [11] No equivalent lemborexant-specific OSA trial has been published as of mid-2025, so clinicians extrapolating from suvorexant data should do so with caution given pharmacokinetic differences between the two agents.

Patients with severe OSA who are non-adherent to positive airway pressure therapy represent a population where lemborexant may pose disproportionate respiratory risk. Starting at 5 mg and reviewing overnight oximetry data before continuing is a practical clinical approach.

Abuse Potential and Physical Dependence

Lemborexant is a Schedule IV controlled substance under the Controlled Substances Act. Its abuse potential was assessed in a human abuse potential study comparing lemborexant 10 mg, 20 mg (supratherapeutic), and 30 mg against placebo, zolpidem 10 mg, and supratherapeutic zolpidem 20 mg. [8]

Findings From the Abuse Potential Study

At the 10 mg therapeutic dose, lemborexant produced "drug liking" scores statistically comparable to placebo and numerically lower than zolpidem 10 mg. At the supratherapeutic 20 mg dose, drug liking scores rose and were not significantly different from zolpidem 10 mg, suggesting that at escalated doses the abuse-potential gap narrows. [8] Patients with a history of substance use disorder should be monitored closely and prescribed the lowest effective dose.

Physical dependence and rebound insomnia were evaluated in the SUNRISE-2 discontinuation phase. Abrupt discontinuation of lemborexant 10 mg after 12 months of use produced mild rebound insomnia in a minority of patients, but no withdrawal syndrome meeting DSM-5 criteria was observed. [5] Slow tapering over 1 to 2 weeks is still recommended in clinical practice to minimize rebound effects.

Drug Interactions That Amplify Serious Risks

Several drug interactions documented in the FDA label can convert manageable sedation into serious CNS depression.

CYP3A4 Inhibitors

Lemborexant is metabolized primarily by CYP3A4. Co-administration with strong CYP3A4 inhibitors such as itraconazole, ketoconazole, clarithromycin, and ritonavir is contraindicated because plasma lemborexant concentrations increase several-fold, greatly amplifying sedation and impairment risk. [3] Moderate CYP3A4 inhibitors (fluconazole, diltiazem, verapamil) require dose reduction to lemborexant 5 mg with careful monitoring.

CYP3A4 Inducers

Strong CYP3A4 inducers such as rifampin and carbamazepine reduce lemborexant exposure to potentially sub-therapeutic levels. Co-administration with strong inducers should be avoided. Moderate inducers require clinical reassessment of efficacy. [3]

Other CNS Depressants

As noted in the CNS depression section, any drug that suppresses CNS activity adds to lemborexant's sedating effects. Clinicians should perform a full medication reconciliation before prescribing, paying particular attention to gabapentinoids, low-dose quetiapine used off-label for insomnia, muscle relaxants, and first-generation antihistamines. [3]

Special Populations With Elevated Risk

Elderly Patients

Adults 65 and older show approximately 20% higher area under the curve (AUC) for lemborexant compared with younger adults, driven by lower clearance. The FDA label recommends starting at 5 mg in this group. [3] Falls and fall-related fractures are a particular concern in elderly patients taking any sedative-hypnotic. A 2020 population-based cohort study in BMJ Open found that newer-generation sleep medications including orexin antagonists were associated with an adjusted odds ratio of 1.42 (95% CI 1.18 to 1.71) for injurious falls compared with non-users, though lemborexant-specific data within that analysis were limited by sample size. [12]

Patients With Hepatic Impairment

Moderate hepatic impairment (Child-Pugh B) increases lemborexant AUC by approximately 2-fold. The label recommends a maximum dose of 5 mg in this population. Severe hepatic impairment (Child-Pugh C) is a contraindication. [3]

Pregnancy and Lactation

Lemborexant has no adequate human pregnancy data. Animal reproduction studies at exposures exceeding the recommended human dose showed adverse developmental effects. [3] The drug should be avoided during pregnancy. No data exist on the presence of lemborexant in human breast milk; the label advises clinicians to consider the developmental risk to the infant before recommending use in lactating patients.

Reporting Serious Adverse Events

Any suspected serious adverse event associated with lemborexant should be reported to the FDA MedWatch program at fda.gov/safety/medwatch. Clinicians in the United States are encouraged to submit FAERS reports for complex sleep behaviors, falls, respiratory events, and psychiatric reactions encountered in post-market practice. Voluntary reporting improves pharmacovigilance signal detection for rare events that trial programs are underpowered to capture. [13]